NANOSONICS LIMITED — Director's Dealing 2015

May 27, 2015

==> picture [202 x 57] intentionally omitted <==

28 May 2015

Company Announcements Office Australian Securities Exchange

Appendix 3Y Change of Director’s Interest Notice

Attached is an Appendix 3Y- Change of Director’s Interest Notice in respect of changes in the relevant interests in securities held by Mr Maurie Stang, Non-Executive Chairman of Nanosonics.

Mr Stang has completed an on-market sale of 3,302,723 ordinary shares in Nanosonics Limited which was made in compliance with the Company’s Secuities Trading Policy. Following the sale, Mr Stang is Nanosonics’ largest shareholder with 25,099,701 ordinary shares representing 8.9% of the Company’s issued share capital.

McGregor Grant Secretary

For more information please contact:

Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600 Kyahn Williamson, Investor Relations, Buchan Consulting on (03) 9866 4722 Ben Walsh, Media Relations, Buchan Consulting on (03) 9866 4722.

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company’s first product is designed to disinfect Ultrasound Transducers. For more information about Nanosonics please visit www.nanosonics.com.au

Nanosonics Limited ABN 11 095 076 896 Unit 24 566 Gardeners Road, Alexandria NSW 2015 Australia Tel: +61 2 8063 1600 Fax: +61 2 8063 1600 Email: info@nanosonics.com.au w: www.nanosonics.com.au

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	Nanosonics Limited
ABN	11 095 076 896

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maurie Stang
Date of last notice	16 July 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest
	a)Direct
	b) Indirect
Nature of indirect interest
(including registered holder)	Indirect shares held in names of Novapharm
Note: Provide details of the circumstances giving rise to the relevantinterest.	Research (Australia) Pty Ltd and EpitekCorporation Pty Ltd
Date of change	26 May2015
No. of securities held prior to change	a)Direct: 28,286,056 ordinary shares, fully
	paid.
	b) Indirect: 116,368 ordinary shares, fully
	paid.
Class
	Ordinary shares, fully paid.
Number acquired	Nil
Number disposed	3,302,723
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation	$6,043,983.09

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	c)Direct: 24,983,333 ordinary shares, fullypaid.d) Indirect: 116,368 ordinary shares, fullypaid.
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestmentplan, participation in buy-back	On-market sale of ordinary shares.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities
Date of change
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relation to which theinterest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimatedvaluation
Interest after change

Part 3 –[+] Closed period

Part 3 – +Closed period
Were the interests in the securities or contracts detailedabove traded during a +closed period where prior writtenclearance was required?	No
If so, was prior written clearance provided to allow the tradeto proceed during this period?
If prior written clearance was provided, on what date was thisprovided?

Director: Maurie Stang Date 28 May 2015

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002